pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·28m ago·1 min read
save

ARPA-H grants up to $125M to accelerate on-demand custom RNA therapy manufacturing

Sep 1, 2026·read at Endpoints ↗DealPositive

ARPA-H announced a new funding initiative aimed at speeding the creation of personalized RNA medicines. The agency will provide up to $125 million in total awards.

Five research groups were selected to receive the grants. Their projects will focus on building platforms that can produce custom RNA therapeutics quickly and on demand.

The effort is intended to shorten development timelines and lower costs for gene-based treatments, supporting the broader goal of making precision medicines more accessible.

The funding reflects the federal government’s commitment to advancing advanced manufacturing technologies in the biotech sector.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “ARPA-H awards $125M for manufacturing custom RNA therapies on demand”

read at Endpoints ↗
83 words · retrieved 26m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RNA Therapeutics IncSionna Therapeutics, Inc.

related stories

  • Jun 3Mineralys makes money moves before looming hypertension approvalEndpoints
  • Jun 2#ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutEndpoints
  • Jun 2Praxis sinks on late-stage study fail for seizure pill, halts second trialEndpoints
  • May 29#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorEndpoints
  • May 16Makary resigns; Biogen reports Alzheimer’s data; and moreEndpoints